anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Prior to randomization, all subjects will participate in a 1-week open-label placebo lead-in trial. Each subject will be administered the placebo nasal spray at Stanford University and then their parent will continue administering the nasal spray to the subject for 1 week at home. Each subject will then be randomly assigned either to the active group or to the placebo (stratified by gender) and will be given the appropriate nasal spray bottle and their parents will be responsible for administering 3 puffs per nostril (4 IU/puff) to their child for a total dose of 24 IU oxytocin or placebo twice daily (BID; morning and evening) for 4-weeks. On completion of this 4-week treatment trial subjects will have the option of participating in a second double-blind trial in which they will be assigned to the alternate nasal spray, to that which they received during the first 4-week trial, for an additional 4-week period.
The invention discloses a flos carthami pseudo-ginseng liquor capable of invigorating blood circulation and dispelling wind. The flos carthami pseudo-ginseng liquor is prepared from, by weight, 30g of pseudo-ginseng, 50g of flos carthami, 20g of angelica sinensis, 20g of astragalus membranaceus, and 1kg of baijiu. A preparation method comprises following steps: pseudo-ginseng, angelica sinensis, and astragalus membranaceus are smashed into crude powder, and are immersed in baijiu via cold method in a container for 30 days; residue is removed; filtering and clarification are carried out; and alcohol degree is adjusted so as to obtain a finished product. The prepared medicinal liquor is brownish red, transparent, mellow, fragrant, and sweet; alcohol degree ranges from 30 to 53 DEG; and sugar content ranges from 6.5 to 10%. The flos carthami pseudo-ginseng liquor can be used for treating extravasated blood, tendons and muscles stagnation, and irregular menstruation, amenorrhea, dysmenorrheal, and postpartum abdominal pain of women. Frequent drinking of the flos carthami pseudo-ginseng liquor possesses excellent effect in wind dispelling, menstrual flow stimulating and blood circulation invigorating, muscles and tendons relaxing, liver-yang suppressing, and swelling and pain relieving.
The invention provides a use of a composition of lavender essential oil and grape seed extract in preparation of antioxidation health products or drugs. The invention also provides an antioxidation health or pharmaceutical composition. The antioxidation health or pharmaceutical composition comprises, by weight, 15-20 parts of lavender essential oil, 30-35 parts of grape seed extract and 1-3 parts of an anti-oxidant. The invention also provides a preparation method and a use of the pharmaceutical composition. The antioxidation health or pharmaceutical composition can realize essential oil oral administration. Through combination of the grape seed extract and lavender essential oil, a cell active oxygen removal capability is improved and cooperative synergism is improved.
The incidence rate of tinnitus is very high globally and shows an increasing trend year by year. Sudden sensorineural hearing loss (SSNHL) , a prevalent otolaryngological emergency, often coincides with tinnitus among its patient population. This condition can significantly impact individuals' interpersonal relationships, work performance, and daily functioning, ultimately leading to a diminished quality of life and even psychological disturbances, such as anxiety and depression. Consequently, it is imperative to expore the mechanisms underlying the emergence and chronicity of tinnitus following SSNHL, and to devise targeted intervention strategies aimed at preventing the chronicity of tinnitus.

This study aims to enroll 30 patients with SSNHL accompanied by tinnitus, 30 patients with SSNHL without tinnitus, and 30 healthy subjects. Investigators will record general demographic information, tinnitus symptom characteristics, audiological examinations, vestibular function tests, and other information for each group during the acute phase of SSNHL onset. Using functional magnetic resonance imaging (fMRI), investigators will compare the brain functional states of patients with SSNHL accompanied by tinnitus and those without tinnitus during the acute phase to investigate the peripheral influencing factors and central mechanisms of tinnitus production. Additionally, investigators will conduct metabolomics analysis to compare the serum metabolite profiles of these two patient groups to identify serum metabolic biomarkers and prognostic biomarkers for tinnitus in patients with SSNHL accompanied by tinnitus. Furthermore, this study will conduct follow-up assessments on the subjects at 1 month, 3 months, and 6 months after the onset of SSNHL, reviewing changes in their symptom characteristics, audiological examinations, and fMRI. At 6 months after the onset, patients will be divided into a tinnitus recovery group and a tinnitus non-recovery group based on their tinnitus recovery status. Investigators will compare the general demographic characteristics, audiological examinations, and brain functional MRI findings between the two groups to explore the role and mechanisms of brain plasticity changes in the recovery or chronicity of tinnitus in patients with SSNHL.
Based on its mechanism of action and findings in animal studies, TYKERB can cause fetal harm when administered to a pregnant woman. In animal reproductive studies, administration of lapatinib to pregnant rats during the period of organogenesis and through lactation led to death of offspring within the first 4 days after birth at maternal exposures that were ≥ 3.3 times the human clinical exposure based on AUC following 1,250 mg dose of lapatinib plus capecitabine. When administered to pregnant animals during the period of organogenesis, lapatinib caused fetal anomalies (rats) or abortions (rabbits) at maternally toxic doses (with maternal exposures approximately 6.4 and 0.2 times, respectively, the human clinical exposure based on AUC following 1,250 mg dose of lapatinib plus capecitabine).

Advise pregnant women and females of reproductive potential of the potential risk to the fetus [see Use in Specific Populations (8.1) and Clinical Pharmacology (12.1)]. Verify the pregnancy status of females of reproductive potential prior to initiation of TYKERB. Advise females of reproductive potential to use effective contraception during treatment with TYKERB and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TYKERB and for 1 week after the last dose [see Use in Specific Populations (8.1, 8.3)].
BACKGROUND: Atrial fibrillation (AF) coexisting with coronary artery disease (CAD) remains a prevailing issue that often results in poor short- and long-term patient outcomes. Screening has been proposed as a method to increase AF detection rates and reduce the incidence of poor prognosis through early intervention. Nevertheless, due to the cost implications and uncertainty over the benefits of a systematic screening programme, the International Task Force currently recommends against screening. This study is to employ Bayesian networks (BN) for assessing the pre-test probability (PTP) of AF in patients with CAD.
METHODS: A total of 12,552 patients with CAD were divided into the CAD patients with AF group (CHD-AF group) and the CAD patients without AF group (non-AF group). Univariate analysis and LASSO regression method were used to screen for potential risk factors. The maximum-minimum climb (MMHC) algorithm was used to construct the directed acyclic graph (DAG) of BN. Predictive power was tested using internal validation, external validation and 10-fold internal cross-validation. Finally, the generated BN model was compared with four machine learning algorithms.
RESULTS: Fourteen indicators were included in the BN, including age, gender, systolic blood pressure (SBP), low-density lipoprotein cholesterol (LDL-C), serum uric acid (UA), gamma-glutamyltransferase (GGT), direct bilirubin (DBIL), lipoproteins [LP(a)], NYHA cardiac function grading, diabetes mellitus and hypertension, palpitation, dyspnoea and the left atrial diameter. The BN model performs well on both the test set (AUC = 0.90) and internal 10-fold cross-validation (AUC = 0.89 ± 0.01).
CONCLUSION: The prediction model of AF with CAD constructed based on BN has high prediction performance and may provide a new tool for large-scale AF screening.
A method and apparatus for verification of the identity of a patient undergoing treatment administered in a treatment room. An identifying element such as a patient chart or patient photograph is provided for the patient which includes a patient identifier, e.g., a barcode, capable of being read by a reader device (15A). The patient identifier is read by the reader (15B). A characteristic audio signal, e.g. a chord previously assigned to the patient and known to the patient, is generated (17A) in response to the matching of the barcode with a stored identifier for the patient. Treatment is at least temporarily withheld if the chord is not the one assigned to the patient.
Elevated skeletal muscle diacylglycerols (DAGs) and ceramides can impair insulin signaling, and acylcarnitines (acylCNs) reflect impaired mitochondrial fatty acid oxidation, thus, the intramuscular lipid profile is indicative of insulin resistance. Acute (i.e., postprandial) hyperinsulinemia has been shown to elevate lipid concentrations in healthy muscle and is an independent risk factor for type 2 diabetes (T2D). However, it is unclear how the relationship between acute hyperinsulinemia and the muscle lipidome interacts across metabolic phenotypes, thus contributing to or exacerbating insulin resistance. We therefore investigated the impact of acute hyperinsulinemia on the skeletal muscle lipid profile to help characterize the physiological basis in which hyperinsulinemia elevates T2D risk. In a cross-sectional comparison, endurance athletes (n = 12), sedentary lean adults (n = 12), and individuals with obesity (n = 13) and T2D (n = 7) underwent a hyperinsulinemic-euglycemic clamp with muscle biopsies. Although there were no significant differences in total 1,2-DAG fluctuations, there was a 2% decrease in athletes versus a 53% increase in T2D during acute hyperinsulinemia (P = 0.087). Moreover, C18 1,2-DAG species increased during the clamp with T2D only, which negatively correlated with insulin sensitivity (P < 0.050). Basal muscle C18:0 total ceramides were elevated with T2D (P = 0.029), but not altered by clamp. Acylcarnitines were universally lowered during hyperinsulinemia, with more robust reductions of 80% in athletes compared with only 46% with T2D (albeit not statistically significant, main effect of group, P = 0.624). Similar fluctuations with acute hyperinsulinemia increasing 1,2 DAGs in insulin-resistant phenotypes and universally lowering acylcarnitines were observed in male mice. In conclusion, acute hyperinsulinemia elevates muscle 1,2-DAG levels with insulin-resistant phenotypes. This suggests a possible dysregulation of intramuscular lipid metabolism in the fed state in individuals with low insulin sensitivity, which may exacerbate insulin resistance.NEW & NOTEWORTHY Postprandial hyperinsulinemia is a risk factor for type 2 diabetes and may increase muscle lipids. However, it is unclear how the relationship between acute hyperinsulinemia and the muscle lipidome interacts across metabolic phenotypes, thus contributing to insulin resistance. We observed that acute hyperinsulinemia elevates muscle 1,2-DAGs in insulin-resistant phenotypes, whereas ceramides were unaltered. Insulin-mediated acylcarnitine reductions are also hindered with high-fat feeding. The postprandial period may exacerbate insulin resistance in metabolically unhealthy phenotypes.
Consists of 3 interdisciplinary educational sessions and Face-to-face with a fortnightly telephone follow-up and text messages. Each session will be directed by medical staff (cardiologist and / or physiatrist) and supported by other health professionals (physical therapist, occupational therapist, nutritionist and psychologist). The educational sessions, include the topics "knowledge of the disease", "recognition of alarm signs", "pharmacological treatment", "healthy lifestyle habits", "mental health" and "regular aerobic exercise"; The entire educational component will be based on the Colombian clinical practice guide for the prevention, diagnosis, treatment and rehabilitation of heart failure.
BACKGROUND: Low back pain (LBP) is a common and disabling musculoskeletal disorder. LBP experiences and expectations can vary from one person to another and influence their clinical outcomes. Despite the existence of numerous evidence-based treatment recommendations, LBP management in primary care remains challenging. This study aims to investigate the experiences and expectations of patients with LPB in primary care settings.
METHODS: A qualitative study with an inductive thematic analysis was conducted. Semi-structured interviews were performed using individuals who had experienced LBP in the past year and had consulted a family physician (FP) or a physiotherapist (PT).
RESULTS: Ten participants with LBP were interviewed (5 women, 5 men, mean age 49 ± 17). Five themes were identified: (1) I am always upset because I can't do anything; (2) I waited to consult; I thought it would go away; (3) I want to see what is going on with my LBP; (4) I want to see the person that will provide the right treatment; (5) I need support to get over it. Participants consulted when their pain was severe and disabling. They expected an imaging test to explain the cause of their LBP and placed more importance on the imaging test results than the FP's or PT's evaluation. Their opinions on care selection and being listened to were important for the participants.
CONCLUSION: This study has highlighted the importance of the patient's point of view in their care. This consideration is important to ensure a comprehensive and collaborative approach with evidence-based practice care.
CHS All Stars is an ancillary study of the Cardiovascular Health Study (CHS), a longitudinal, observational, population-based study of the onset, progression, and course of heart disease and stroke in the elderly which began in 1988. The All Stars study reexamined the survivors of CHS to determine the likelihood of maintaining function later in life. A focus was to determine whether age-related biological factors are long-term predicators of functional aging which was assessed through a follow-up exam (Yr 18 visit conducted in 2005-06, n=1674 older adults, mean age =84 years) and 3 yrs of subsequent 6 month interval phone contacts. Vitamin D status (serum 25(OH)D and PTH) is being assessed in all CHS All Stars participants who provided a blood sample at the Yr 18 visit (n\~1100).
In Period 1, participants will be dosed with a single administration of tolbutamide 500 mg tablet on Day 1. Period 1 will be immediately followed by Period 2 with no washout. In Period 2, participants will be dosed with oral 200 mg ritlecitinib QD for 10 days followed by administration of a single dose of 500 mg tolbutamide oral tablet within approximately 5 minutes after administration of a 200 mg dose of ritlecitinib on the morning of Day 10.
Injectable or implantable drug delivery systems providing on-demand ultrasound-triggered drug release and methods for controlling the release of drug in a patient are provided herein. The on-demand drug delivery systems contain a drug depot and a drug encapsulated in an encapsulating material, where the encapsulating material is different from the depot. In the preferred embodiment, the depot also contains microbubbles that encapsulate one or more gases. The microbubbles enhance the drug release when ultrasound is applied compared to the same system in the absence of microbubbles. In a preferred embodiment, the drug delivery system, contains an encapsulating material, preferably liposomes, a drug to be delivered, microbubbles, and at least two hydrogel-forming precursor components. Following injection or implantation, the patient can control the time, location and dosage released by administering ultrasound.
Patients receive bryostatin 1 IV over 1 hour on days 1, 8, 15, and 22 and temsirolimus IV over 30 minutes once on days 8, 15, and 22 during course 1. On subsequent courses patients receive bryostatin 1 and temsirolimus once on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Over the next 20 years, the number of total hip arthroplasties (THAs) performed to alleviate pain and disability associated with osteoarthritis (OA) is expected to double to more than 500,000/year. Most patients report improved health-related quality of life following surgery; however, deficits in physical function and quality of life persist. Specifically, Veterans with THA have a higher prevalence of severe activities of daily living (ADL) limitations and report severe physical health-related quality of life deficits. The increased THA utilization, combined with long-term functional deficits which increase heath care utilization, suggests a need for targeted rehabilitation strategies to improve physical function for Veterans after THA.

Movement compensations are a biomarker of functional decline in a variety of older adult populations. For patients with THA, persistent movement compensations are seen in activities of daily living, such as level walking, sit-to-stand transitions, and stair climbing. These movement compensations likely stem from a combination of poor muscle strength and a failure to integrate available muscle strength into functional movement. Functional strength integration (FSI) during daily tasks refers to the ability of the body to produce stable, coordinated movements. At the hip joint, optimal FSI is largely dependent on the ability of hip abductor muscles to produce sufficient hip abduction moments to stabilize the pelvis during unilateral stance tasks. Thus, inability to integrate hip abductor muscle strength during functional tasks results in poor pelvic stability and movement compensations. Lack of FSI possibly explains the deficits in functional recovery after THA. However, current rehabilitation practices do not target the integration of strength and functional movement to resolve movement compensations.

Rehabilitation emphasizing functional strength integration after THA has the potential to substantially improve postoperative physical function by remediating movement compensations with greater hip abductor strength and recruitment during function, providing greater pelvic control and better movement quality. Therefore, the investigators propose a randomized controlled trial of 100 participants to determine if an 8-week functional strength integration (FSI) program after THA improves physical function and muscle performance more than control intervention (CON) after unilateral THA. The secondary goal is to determine if FSI improves movement compensations during functional activity (walking and stair climbing). Eight weeks of intervention will be initiated 2 weeks after THA to allow for early tissue healing. Outcomes will be assessed pre-operatively (PRE); intervention mid-point (after 4 weeks intervention; POST1); intervention end-point (after 8 weeks intervention; POST2) (primary endpoint); and late recovery (26 weeks after initiating rehabilitation; POST3).
Medicament which induces the natural defence (antibodies and/or leucocytes or cellular reaction) of the organism by local action comprises (a) the spores of the higher fungi Daldinia concentrica or (b) a solution of the protein secreted by the spores when they are germinated in a 5% glucose or saccharose culture medium. the medicament is an immunostimulant not an antibiotic. Immunostimulant used against bacterial or viral, local toxic infections or infections. The medicament also has antibiotic activity against some yeastes. When used to dust wounds (without any other aseptic treatment) no inflammation is observed, cicatrisation is complete within about 48 hrs and all traces of scar tissue disappear within a few weeks. The medicament is used to treat accidental and surgical wounds, esp. in cases of aesthetic surgery or to treat wounds which one normal need an antitetanus injection.
The present invention relates to a method for preparing digestion-promoting spleen-invigorating soymilk powder with micron chicken's gizzard-skin powder, micro coix seed powder, micron white hyacinth bean powder, micron yam powder and micron pine pollen. The digestion-promoting spleen-invigorating soymilk powder is formed by that the micron chicken's gizzard-skin powder, the micro coix seed powder, the micron white hyacinth bean powder, the micron yam powder, the micron pine pollen and oligosaccharide raw material through high-technology airflow superfine grinding processing are added into different soymilk powder and combined and processed. The digestion-promoting spleen-invigorating soymilk powder has the obvious functions of promoting digestion and invigorating spleens and also has the effects of alloying fatigue, enhancing immunity, etc. The old, the middle-aged and the young with spleen deficiency and general deficiency can obtain scores of nutrient substances such as abundant protein, vitamins, mineral substances, active ferment, etc., and the digestion-promoting spleen-invigorating soymilk powder simultaneously strengthens the health-care functions of promoting digestion, invigorating spleens, alloying fatigue, regulating immunity, reducing blood fat, etc. because the ingredient of the pine pollen which is extolled as a Chinese special product and a miniature nutrient treasury is added. Therefore, the present invention is a favorable method for preparing the digestion-promoting spleen-invigorating soymilk powder which has Chinese characteristics and is especially designed for the old, the middle-aged and the young with incoordination between spleens and stomachs, constitutional deficiency, indigestion or poor appetite all over the world.
Hyperthermia induced by phenethylamines, such as 3,4-methylenedioxymethamphetamine (MDMA), can lead to life-threatening complications and death. Activation of the sympathetic nervous system and subsequent release of norepinephrine and activation of uncoupling proteins have been demonstrated to be the key mediators of phenethylamine-induced hyperthermia (PIH). Recently, the gut microbiome was shown to also play a contributing role in PIH. Here, the hypothesis that bile acids (BAs) produced by the gut microbiome are essential to PIH was tested. Changes in the serum concentrations of unconjugated primary BAs cholic acid (CA) and chenodeoxycholic acid (CDCA) and secondary BA deoxycholic acid (DCA) were measured following MDMA (20 mg/kg, sc) treatment in antibiotic treated and control rats. MDMA-induced a significant hyperthermic response and reduced the serum concentrations of three BAs 60 min post-treatment. Pretreatment with antibiotics (vancomycin, bacitracin and neomycin) in the drinking water for five days resulted in the depletion of BAs and a hypothermic response to MDMA. Gut bacterial communities in the antibiotic-treated group were distinct from the MDMA or saline treatment groups, with decreased microbiome diversity and alteration in taxa. Metagenomic functions inferred using the bioinformatic tool PICRUSt2 on 16S rRNA gene sequences indicated that bacterial genes associated to BA metabolism are less abundant in the antibiotic-MDMA treated group. Overall, these findings suggest that gut bacterial produced BAs might play an important role in MDMA-induced hyperthermia.